NCT02729961: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma |
|
|
| Withdrawn | 1/2 | 0 | US | Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Ceritinib, LDK 378, LDK378, Zykadia, Laboratory Biomarker Analysis, Pharmacological Study | University of Washington, National Cancer Institute (NCI) | Anaplastic Large Cell Lymphoma, ALK-Positive, CD30-Positive Neoplastic Cells Present, Systemic Anaplastic Large Cell Lymphoma | 07/23 | 07/23 | | |
